Indian Pharma Capex 2026: Cleanroom Demand

India's pharmaceutical manufacturing sector is entering another significant investment cycle in 2026. After several years of capacity expansion, regulatory upgrades and supply-chain diversification, pharmaceutical companies are allocating substantial capital toward new manufacturing facilities, capacity additions, complex products, biologics, injectables and technology upgrades.

For companies supplying cleanroom equipment, this investment cycle is particularly important.

Pharmaceutical capital expenditure does not translate into cleanroom demand on a one-to-one basis. However, new sterile manufacturing capacity, regulated-market expansion and modernization of existing facilities create demand for HVAC systems, cleanroom infrastructure, particle monitoring, environmental monitoring, isolators, RABS, pass boxes, air showers, pressure monitoring and other contamination-control technologies.

According to ICRA estimates reported in September 2025, Indian pharmaceutical companies were expected to undertake approximately ₹42,000–45,000 crore of capex in FY2026, including around ₹25,000 crore of inorganic investments.

At the broader industry level, a 2025 SEBI-filed industry analysis estimated Indian pharmaceutical capex at approximately ₹90,000–95,000 crore during FY2021–FY2025, with expected investment of approximately ₹1.40–1.45 lakh crore during FY2026–FY2030—roughly 1.5 times the previous five-year period.

These figures indicate a substantial opportunity for pharmaceutical infrastructure and cleanroom-equipment suppliers.

1. FY2026 Pharma Capex Is Estimated at ₹42,000–45,000 Crore

One of the most important figures for the Indian pharma capex 2026 outlook is ICRA's FY2026 estimate of ₹42,000–45,000 crore for Indian pharmaceutical companies.

The investment includes both organic expansion and inorganic activity.

This spending can support:

• New manufacturing facilities
• Capacity expansion
• Acquisitions
• R&D infrastructure
• Injectable facilities
• Complex generics
• Biologics
• Compliance upgrades

For cleanroom-equipment suppliers, the most relevant portion is capital directed toward manufacturing and regulated-product capacity.

2. Pharmaceutical Capex Could Reach ₹1.40–1.45 Lakh Crore Through FY2030

The medium-term outlook is even more significant.

Industry analysis filed with SEBI estimates pharmaceutical-related capex could rise to approximately ₹1.40–1.45 lakh crore between FY2026 and FY2030, compared with approximately ₹90,000–95,000 crore during FY2021–FY2025.

That represents an estimated increase of around 1.5 times.

This creates a multi-year opportunity rather than a single-year spike.

3. Why Capex Is Increasing

Several structural factors are driving pharmaceutical investment.

Capacity expansion

Companies are increasing capacity to serve growing domestic and international demand.

Complex products

Investment is shifting toward:

• Complex generics
• Injectables
• Biosimilars
• Peptides
• Oncology products
• Drug-device combinations

Supply-chain resilience

Manufacturers are increasing domestic production of APIs and other critical pharmaceutical inputs.

Regulatory readiness

Facilities supplying regulated markets require continuous investment in GMP infrastructure and contamination control.

4. PLI Schemes Are Supporting New Pharmaceutical Manufacturing

Government incentives are an important part of the investment environment.

Under the pharmaceutical PLI scheme, cumulative investments across the pharmaceutical and bulk-drug programs reached approximately ₹41,943 crore as of December 2025, according to government-reported data. The investment was more than twice the original committed target of ₹17,275 crore.

This investment supports manufacturing capacity across several pharmaceutical categories.

The impact on cleanroom demand is indirect but important: every new GMP manufacturing project creates requirements for qualified facilities, utilities and controlled environments.

5. Bulk Drug PLI Has Generated ₹4,814 Crore of Investment

Under the PLI scheme specifically focused on critical KSMs, drug intermediates and APIs, actual investment reached approximately ₹4,814 crore by December 2025, exceeding the committed investment of ₹4,329.95 crore.

The scheme had also resulted in approximately 56,800 tonnes per year of manufacturing capacity across 28 critical products by December 2025.

Although API manufacturing is not necessarily sterile manufacturing, new pharmaceutical industrial infrastructure creates broader demand for controlled environments, laboratory facilities and GMP utilities.

6. Biologics Are Creating Higher-Value Cleanroom Opportunities

India's 2026 policy environment is increasingly focused on biologics and biosimilars.

The government has announced Biopharma SHAKTI, with an outlay of ₹10,000 crore over five years, intended to strengthen India's domestic biopharmaceutical ecosystem and support global competitiveness in biologics and biosimilars.

Biopharmaceutical facilities often require sophisticated contamination-control infrastructure.

This can increase demand for:

• Cleanroom HVAC
• HEPA filtration
• Environmental monitoring
• Pressure monitoring
• Particle counters
• Biosafety-related infrastructure
• Controlled material transfer
• Process containment

7. Sterile Injectable Capacity Is an Important Capex Driver

Complex sterile injectables represent an attractive area for Indian manufacturers and CDMOs.

A March 2026 industry report highlighted expansion by Indian CDMOs into complex products, including sterile injectables, peptides, ADCs and oligonucleotides.

Sterile facilities have significantly higher contamination-control requirements than many conventional pharmaceutical manufacturing areas.

A new sterile facility may require:

• Grade A/B/C/D classified areas
• HVAC systems
• HEPA filtration
• Airflow visualization
• Particle monitoring
• Microbial monitoring
• Isolators or RABS
• Sterile transfer systems
• Pressure monitoring

Therefore, sterile manufacturing expansion can have a disproportionately strong impact on specialized cleanroom-equipment demand.

8. Cleanroom HVAC Will Remain a Major Investment Category

HVAC is one of the most capital-intensive components of a pharmaceutical cleanroom.

A pharmaceutical HVAC system must support:

• Temperature control
• Relative humidity
• Air changes
• Pressure cascades
• Filtration
• Airflow direction
• Environmental stability

For sterile manufacturing, HVAC design becomes even more critical because airflow is part of the contamination-control strategy.

The investment opportunity therefore extends beyond constructing rooms themselves to include controls, monitoring and qualification.

9. Environmental Monitoring Demand Will Increase

As pharmaceutical manufacturers invest in new cleanrooms, demand for environmental monitoring equipment is expected to increase.

Relevant equipment includes:

Non-viable particle monitoring

Used to monitor airborne particulate contamination.

Microbial air samplers

Used to evaluate viable airborne microorganisms.

Surface monitoring systems

Used to assess microbial contamination on surfaces.

Differential-pressure monitoring

Used to verify pressure relationships between classified areas.

Temperature and humidity monitoring

Used to verify environmental conditions.

The expansion of digital monitoring can also create demand for software with audit trails, electronic records and data-integrity controls.

10. EU GMP Annex 1 Is Influencing Equipment Selection

The revised EU GMP Annex 1 has increased emphasis on contamination-control strategy and risk-based sterile manufacturing.

Indian manufacturers supplying European markets are therefore increasingly evaluating:

• Isolators
• RABS
• Continuous particle monitoring
• Glove integrity testing
• Automated environmental monitoring
• Validated decontamination
• Digital data systems

This means cleanroom-equipment purchasing decisions increasingly involve compliance capability, not simply equipment specifications.

11. Isolator and RABS Demand Could Benefit From Sterile Capex

Barrier technology is becoming increasingly important in aseptic manufacturing.

Isolators can reduce direct operator interaction with critical processing zones, while RABS can provide physical separation and improved contamination control.

New injectable projects may therefore allocate substantial capital to:

• Filling-line isolators
• Vial handling systems
• Glove ports
• Rapid transfer systems
• Bio-decontamination systems
• Glove integrity testing

This creates opportunities for specialized equipment suppliers alongside traditional cleanroom contractors.

12. Particle Monitoring Is Becoming a Strategic Purchase

Pharmaceutical companies are moving beyond occasional manual measurements toward more comprehensive monitoring strategies.

Demand can therefore increase for:

• Portable particle counters
• Online particle counters
• Remote particle monitoring
• Multi-channel environmental monitoring
• Automated alarms
• Electronic reporting

For cleanroom suppliers, integrating monitoring into the overall facility design can provide additional value compared with selling standalone equipment.

13. Capex Is Moving Toward Technology-Intensive Manufacturing

A key trend is that pharmaceutical companies are not simply building more capacity.

They are increasingly building higher-quality and more technologically advanced capacity.

Examples include:

• Automated filling
• Robotics
• Digital batch records
• Automated inspection
• Continuous environmental monitoring
• Process analytical technology
• Advanced laboratory instrumentation

A March 2026 report on Indian CDMOs described the current expansion as increasingly focused on higher-complexity, technology-driven capabilities rather than simple capacity additions.

14. Individual Company Investments Illustrate the Trend

Company-level investments provide useful evidence of the broader capex cycle.

For example, Lupin reported approximately ₹2,523 crore of capital expenditure in FY2026, supporting manufacturing reliability, injectables and inhalation platforms, digital infrastructure and compliance readiness.

This illustrates how pharmaceutical capex can combine:

• Capacity
• Compliance
• Technology
• Manufacturing reliability
• Digital transformation

Such projects can generate demand across the pharmaceutical engineering ecosystem.

15. What This Means for Cleanroom Equipment Suppliers

The Indian pharma capex 2026 cycle creates several opportunities for specialized suppliers.

The strongest demand areas are likely to include:

Equipment category	Outlook
Cleanroom HVAC	High
HEPA filtration	High
Particle counters	High
Environmental monitoring	High
Differential-pressure monitoring	High
Isolators	High for sterile projects
RABS	Moderate–High
Glove integrity testers	Growing
Pass boxes	Moderate
Air showers	Moderate
Decontamination systems	Growing
Cleanroom validation	High

The precise demand will vary by project type and manufacturing category.

16. New Projects Will Not Be the Only Source of Demand

An important point for equipment manufacturers is that pharmaceutical capex does not only mean greenfield plants.

Existing facilities also require:

• HVAC upgrades
• Monitoring upgrades
• Energy-efficiency improvements
• Annex 1 remediation
• Equipment replacement
• Automation
• Data-integrity upgrades
• Facility expansion

This creates a recurring aftermarket opportunity.

For suppliers, lifecycle services can therefore be as important as initial equipment sales.

17. Gujarat Could Be an Important Beneficiary

Gujarat remains one of India's major pharmaceutical manufacturing hubs.

Recent reporting indicates that pharmaceutical companies announced approximately ₹2,500 crore of fresh investments in Gujarat in August 2026, reinforcing the state's position as a major pharmaceutical investment destination.

The state's pharmaceutical ecosystem can support demand for:

• Pharmaceutical cleanrooms
• HVAC
• Laboratory infrastructure
• Process equipment
• Environmental monitoring
• Validation services

For suppliers operating in Gujarat and western India, this represents an important regional opportunity.

18. The Outlook Through 2030

The strongest signal is the medium-term investment forecast.

If pharmaceutical capex reaches the estimated ₹1.40–1.45 lakh crore during FY2026–FY2030, cleanroom infrastructure should remain an important component of pharmaceutical manufacturing investment.

However, the market will increasingly reward suppliers that understand pharmaceutical processes rather than simply supplying generic cleanroom hardware.

Customers will increasingly ask:

• Is the equipment GMP-compatible?
• Can it be qualified?
• Does it support data integrity?
• Can it integrate with existing systems?
• Is calibration available?
• What documentation is supplied?
• Can the supplier support validation?

What Should Pharma Companies Prioritize in 2026?

For manufacturers planning new projects or facility upgrades, the priority should be risk-based capital allocation.

A practical sequence is:

1. Define the manufacturing process.
2. Identify contamination risks.
3. Establish cleanroom classifications.
4. Design HVAC and airflow systems.
5. Select appropriate barrier technologies.
6. Establish environmental monitoring requirements.
7. Define data-integrity requirements.
8. Plan qualification and validation.
9. Evaluate lifecycle maintenance costs.
10. Build supplier qualification into procurement.

This approach helps prevent expensive redesigns later in the project.

Conclusion

The Indian pharma capex 2026 outlook points toward another significant period of pharmaceutical infrastructure investment.

ICRA's FY2026 estimate of ₹42,000–45,000 crore in pharmaceutical company capex, combined with the longer-term estimate of approximately ₹1.40–1.45 lakh crore between FY2026 and FY2030, indicates that India's pharmaceutical manufacturing ecosystem is entering a substantial investment cycle.

For cleanroom-equipment suppliers, the opportunity is particularly strong in sterile manufacturing, biologics, injectables, CDMO facilities, environmental monitoring and regulatory upgrades.

The market is also becoming more sophisticated. Pharmaceutical companies increasingly need equipment that can support qualification, validation, data integrity and contamination-control strategies—not simply equipment that meets a basic technical specification.

For manufacturers and suppliers planning their 2026 strategy, the most attractive opportunities will therefore be where capex, regulatory compliance and advanced pharmaceutical manufacturing intersect.